Ina M. Schulz-Jurgenliemk

Utrecht, UT 3584CX, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 146 publications

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial.

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial.

Journal: Obstetrical & gynecological survey

Published: October 30, 2025

Dosimetric comparison between brachytherapy and MR-Linac as a boost modality for locally advanced cervical cancer.

Dosimetric comparison between brachytherapy and MR-Linac as a boost modality for locally advanced cervical cancer.

Journal: Clinical and translational radiation oncology

Published: September 30, 2025

Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.

Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.

Journal: The Lancet. Oncology

Published: June 11, 2025

A review on the transition from PDR to HDR brachytherapy (interventional radiotherapy) for treatment of head and neck cancer: Clinical and practical aspects.

A review on the transition from PDR to HDR brachytherapy (interventional radiotherapy) for treatment of head and neck cancer: Clinical and practical aspects.

Journal: Brachytherapy

Published: April 08, 2025

Joint ABS/GEC-ESTRO Consensus Statement on the objectives of training in brachytherapy for physicians.

Joint ABS/GEC-ESTRO Consensus Statement on the objectives of training in brachytherapy for physicians.

Journal: Brachytherapy

Published: March 12, 2025

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.

Journal: The Lancet. Oncology

Published: February 26, 2025

Age-related differences in patient preferences for adjuvant chemotherapy for high-risk endometrial cancer.

Age-related differences in patient preferences for adjuvant chemotherapy for high-risk endometrial cancer.

Journal: Maturitas

Published: February 24, 2025

Evaluation of brachytherapy applicators and their association with morbidity and local control in cervix cancer: An EMBRACE I analysis.

Evaluation of brachytherapy applicators and their association with morbidity and local control in cervix cancer: An EMBRACE I analysis.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: February 21, 2025

Distant Metastasis After Chemoradiation and Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer.

Distant Metastasis After Chemoradiation and Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer.

Journal: International journal of radiation oncology, biology, physics

Published: January 08, 2025

INTERLACE: not a new standard for cervical cancer chemoradiation.

INTERLACE: not a new standard for cervical cancer chemoradiation.

Journal: Lancet (London, England)

Published: November 11, 2024

Cost-effectiveness of a nurse-led sexual rehabilitation intervention for women treated with radiotherapy for gynaecological cancer in a randomized trial.

Cost-effectiveness of a nurse-led sexual rehabilitation intervention for women treated with radiotherapy for gynaecological cancer in a randomized trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: October 18, 2024

Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.

Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 07, 2024

Showing 1-12 of 146

Last Updated: 09/26/2026